Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03445910
Other study ID # 3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 20, 2018
Est. completion date July 30, 2018

Study information

Verified date August 2018
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite recent advances in clinical and laboratory techniques of Assisted Reproductive Technology (ART), the pregnancy rate remains around 30% per cycle. It has been estimated that 50% to 75% of lost pregnancies are due to failure of implantation.

The process of implantation is a locally controlled paracrine/juxtacrine-mediated phenomenon. Successful implantation depends on the synchronized "cross-talk" between a functional blastocyst and a "receptive" endometrium. This process leads to apposition, attachment and invasion of embryos and subsequent normal placentation. So the objective of this study is investigate the impact of intrauterine injection of human chorionic gonadotropin (hCG) at the day of ovum pick-up on implantation and pregnancy rates in patients with recurrent implantation failure.


Description:

The endometrium can only support implantation during a discrete period of about 6 to 9 days after LH peak; termed the "window of implantation". During this period endometrial glandular epithelium is differentiated into a highly secretory state with the production of various cytokines and growth factors that facilitate implantation. In fact, several substances secreted from the embryo or the endometrium affect implantation. These include cyclic adenosine monophosphate, relaxin, gonadotropin, prostaglandin E2, and glycoprotein hormones.

Human chorionic gonadotropin (hCG) is the earliest blastocyst-derived signals received by the endometrium; it is transcribed as early as the 2-cell embryo stage. It is produced by the trophectodermal cells of the preimplantation blastocyst. Recent evidence suggests that hCG is also produced by the endometrial epithelial cells during the secretory.

It has been shown that intrauterine injection of hCG before embryo transfer significantly improves pregnancy rates in IVF/ICSI cycles.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 30, 2018
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

A- Age between 20 and 35 years old.

B- Patients undergoing ICSI trial after one or more previous failure.

Exclusion Criteria:

A- Females with any local cause, uterine pathology, e.g: uterine myoma or previous myomectomy, endometriosis or the presence of hydrosalpinges.

B- Patients undergoing ICSI trial for the first time.

C- Previous Asherman Syndrome.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Human chorionic gonadotropin
intrauterine injected of 500 IU of hCG on the day of ovum pick-up and

Locations

Country Name City State
Egypt Ain Shams University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary implantation rate is defined as the number of gestational sacs observed at echographic screening at 6 weeks of pregnancy divided by the number of embryos transferred six weeks from the last menstrual period
Secondary biochemical pregnancy defined as positive from quantitative values of serum test of ß human chorionic gonadotropin according to standard values that are used in the laboratory. two weeks following embryo transfere
Secondary clinical pregnancy is defined as viable pregnancy when there is evidence of gestational sac, embryo and fetal heart activity at time of trans-vaginal ultrasound evaluation by the 8th week. eight weeks from last menstrual period
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01933893 - Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients N/A
Recruiting NCT04497558 - The Clinical Efficiency of Tb-ERA in Chinese RIF Patients N/A
Recruiting NCT04867759 - Uterine Natural Killer (uNK) Cell Expression in Patients With Repeated ICSI Failures: A Multicenter Cohort Study
Completed NCT01493440 - Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure N/A
Not yet recruiting NCT02967419 - The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure N/A
Not yet recruiting NCT02893722 - A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment Phase 1
Completed NCT03405883 - Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women
Completed NCT04698109 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gynecological Diseases
Recruiting NCT04533295 - The Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF N/A